Aura Biosciences (AURA) to Offer Common Stock

Aura Biosciences, Inc. (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the launch of an underwritten public offering of its common stock. All shares of common stock to be sold in the offering will be offered by Aura. Aura also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering under the same terms and conditions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

SVB Securities, Cowen and Evercore ISI are acting as joint bookrunning managers for the offering and JMP Securities, a Citizens Company and BTIG are acting as co-managers for the offering.

You May Also Be Interested In

• Abbott Labs (ABT) PT Raised to $135 at TD Cowen
• TD Cowen on Opus Genetics (IRD): 'High Conviction For Meaningful Efficacy'
• Target (TGT) PT Raised to $160 at TD Cowen